These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11157856)

  • 1. Influence of organ site and tumor cell type on MUC1-specific tumor immunity.
    Morikane K; Tempero R; Sivinski CL; Kitajima S; Gendler SJ; Hollingsworth MA
    Int Immunol; 2001 Feb; 13(2):233-40. PubMed ID: 11157856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice.
    Tempero RM; VanLith ML; Morikane K; Rowse GJ; Gendler SJ; Hollingsworth MA
    J Immunol; 1998 Nov; 161(10):5500-6. PubMed ID: 9820526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
    Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
    Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
    Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
    J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
    Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
    Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.
    Mehla K; Tremayne J; Grunkemeyer JA; O'Connell KA; Steele MM; Caffrey TC; Zhu X; Yu F; Singh PK; Schultes BC; Madiyalakan R; Nicodemus CF; Hollingsworth MA
    Cancer Immunol Immunother; 2018 Mar; 67(3):445-457. PubMed ID: 29204701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
    Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
    Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
    BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
    Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
    Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organ-specific pancreatic tumor growth properties and tumor immunity.
    Morikane K; Tempero RM; Sivinski CL; Nomoto M; Van Lith ML; Muto T; Hollingsworth MA
    Cancer Immunol Immunother; 1999 Jan; 47(5):287-96. PubMed ID: 10022473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain.
    Plunkett T; Graham R; Correa I; Sewell R; Miles D; Burchell J; Taylor-Papadimitriou J
    Int J Cancer; 2004 May; 109(5):691-7. PubMed ID: 14999776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses.
    VanLith ML; Kohlgraf KG; Sivinski CL; Tempero RM; Hollingsworth MA
    Int Immunol; 2002 Aug; 14(8):873-82. PubMed ID: 12147624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
    Rowse GJ; Tempero RM; VanLith ML; Hollingsworth MA; Gendler SJ
    Cancer Res; 1998 Jan; 58(2):315-21. PubMed ID: 9443411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.
    Koido S; Tanaka Y; Chen D; Kufe D; Gong J
    J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.
    Turner MS; Cohen PA; Finn OJ
    J Immunol; 2007 Mar; 178(5):2787-93. PubMed ID: 17312122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
    Ryan SO; Turner MS; Gariépy J; Finn OJ
    Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
    Koido S; Enomoto Y; Apostolopoulos V; Gong J
    Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
    Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.